secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026404
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma increases buyback to $325M, announces formal strategic review
--------------------------------------------------------------------------------

- Capital Return Program increased to $325M; $170M remaining expected by end of 2023; $27M repurchased YTD 2023.
- Q4 2022 YUPELRI sales $19.5M (up 27% YoY); TRELEGY global net sales $537M (up 13% YoY).
- Non-GAAP profit expected in 2H 2023; 2023 R&D guidance $35-45M, SG&A $45-55M.
- Appointed Susannah Gray (ex-Royalty Pharma CFO) to Board; Board declassification proposal submitted.
- Announced formal strategic review; responding to Irenic Capital's activist claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923026404/0001104659-23-026404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923026404/tm238017d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer